Proxima, the Roivant‑backed drug‑discovery firm formerly known as VantAI, raised an $80 million seed round to build AI platforms for designing proximity‑based therapeutics that modulate protein interactions. The company said it will combine proteome‑scale structural data with advanced generative models to design proximity‑modulating drugs across oncology and immunology. Investors include DCVC and Roivant affiliates; Proxima framed the raise as enabling rapid progression of multiple preclinical programs and new discovery partnerships.